Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN) (IMPOCNPIC)
Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN): A Descriptive Study of Occupational Issues to Guide Occupational Therapy Intervention
Advances in cancer treatment have increased the number of patients living with long-term treatment-related consequences. Among these, chemotherapy-induced peripheral neuropathy (CIPN) is common and can significantly affect patients' quality of life and daily activities. Despite its impact, CIPN remains difficult to manage, and patients often receive insufficient support regarding its functional and occupational consequences.
Occupational therapy remains underutilised in oncology, despite its potential to help patients maintain or regain independence in meaningful daily activities. Collaboration between Advanced Practice Nurses and occupational therapists could improve the identification and management of occupational difficulties associated with CIPN.
The aim of this study is to describe the occupations affected by CIPN using the Canadian Occupational Performance Measure (COPM). The findings will help identify patients' occupational needs and guide future occupational therapy interventions.
Visão geral do estudo
Status
Status
Condições
Condições
Descrição detalhada
In 2023, 433,136 new cancer cases were reported in France, accounting for 8.1 million hospital admissions. Thanks to advances in cancer treatment, the number of patients living with long-term consequences of cancer or its treatment is steadily increasing.
Cancer control policies in France have been based on successive Cancer Plans, followed by the adoption of the 2021-2030 Ten-Year Cancer Control Strategy. This strategy is structured around four priority areas, including the second: "Reducing long-term consequences and improving quality of life." Indeed, two out of three people experience lasting effects five years after a cancer diagnosis. This priority aims to promote research to reduce long-term consequences and improve patients' quality of life, as well as to prevent, detect and manage the effects associated with the disease and its treatments. In particular, findings from the VICAN 5 study show that 63.5% of cancer survivors continue to experience disease- or treatment-related consequences five years after diagnosis. Among these patients, 35.3% reported neuropathic pain, which negatively affects their quality of life and daily activities. Chemotherapy-induced peripheral neuropathy (CIPN) is common and remains difficult to manage because of its limited response to pharmacological treatments.
Current literature highlights a lack of support and care for patients experiencing CIPN, as well as insufficient knowledge regarding its impact on their daily activities and occupations.
The cancer care pathway can be divided into three main stages: diagnosis disclosure, treatment, and post-cancer care. Advanced Practice Nurses (APNs) can intervene at different stages of this pathway. They play a major role in long-term follow-up, particularly in identifying and monitoring treatment-related side effects and long-term consequences. However, their role, which primarily focuses on screening and monitoring, does not allow them to provide specific interventions aimed at improving the management of CIPN-related difficulties.
Occupational therapy aims to help individuals regain or maintain their independence in carrying out everyday activities. It offers a wide range of interventions but remains underutilised in oncology, for several reasons, including limited awareness of the profession, insufficient knowledge of its potential benefits, and difficulties accessing occupational therapy services.
In the management of CIPN, collaboration between Advanced Practice Nurses and occupational therapists could help establish effective care pathways, combine their respective expertise and promote patients' engagement in activities affected by CIPN.
The objective of this study is to describe the occupations (activities or groups of activities performed regularly and considered meaningful and valuable by individuals) affected by CIPN, using the Canadian Occupational Performance Measure (COPM).
Occupational performance is defined as an individual's ability to perform meaningful occupations adequately, efficiently and to their own satisfaction.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Camille Jung
- Número de telefone: 01 57 02 22 68
- E-mail: Camille.Jung@chicreteil.fr
Locais de estudo
-
-
-
Créteil, França, 94000
- Recrutamento
- Centre Hospitalier Intercommunal de Créteil
-
Contato:
- Claire Devroedt
- Número de telefone: 01 57 02 32 51
- E-mail: Claire.devroedt@chicreteil.fr
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Adult patients with chemotherapy-induced peripheral neuropathy, grade 2 or 3 according to CTCAE: caused by paclitaxel in cases of breast cancer or by oxaliplatin in cases of colorectal cancer.
Patients must be able to carry on a conversation in French.
Descrição
Inclusion Criteria:
- Patient treated for breast cancer or colorectal cancer, who has not previously received paclitaxel or oxaliplatin.
- Patient with grade 2 or 3 peripheral neuropathy, according to the CTCAE criteria, occurring during their treatment.
- Patient able to communicate in French.
- Patient aged 18 years or older
Exclusion Criteria:
- History of neuropathy prior to treatment.
- Refusal to participate in the study.
- Protected persons (pregnant or breastfeeding women, individuals under guardianship or curatorship, minors, individuals deprived of their liberty, or individuals unable to provide informed consent).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: CASE_ONLY
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Description of the occupational issues identified as priorities by patients
Prazo: 3 months
|
Describe the occupational issues identified as priorities by patients based on the categories and subcategories of occupations defined by the MCRO |
3 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient verbatim
Prazo: 3 months
|
Patient verbatim statements regarding their priority occupational issues, grouped according to the MCRO categories and subcategories |
3 months
|
|
Performance and satisfaction scores
Prazo: 3 months
|
Performance and satisfaction scores obtained across each category and subcategory of the MCRO |
3 months
|
|
Number and percentages of priority problematic occupations
Prazo: 3 months
|
Number and percentages of priority problematic occupations, coded according to the categories and subcategories of the MCRO, based on the two types of treatment received. |
3 months
|
|
Number and percentages of priority adverse events
Prazo: 3 months
|
Number and percentages of priority adverse events, coded according to the categories and subcategories of the MCRO, based on the two CTCAE grading scales |
3 months
|
|
Average time to onset of NPICs by treatment received
Prazo: 3 months
|
Average time to onset of NPICs by treatment received. The time to onset of NPICs is defined as the interval (in days) between the start date of treatment and the date of NPIC diagnosis |
3 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Intestinais
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias Intestinais
- Doenças retais
- Doenças do cólon
- Doenças de pele
- Doenças da mama
- Doenças da Pele e do Tecido Conjuntivo
- Neoplasias Colorretais
- Neoplasias da Mama
Outros números de identificação do estudo
Outros números de identificação do estudo
- IMPOC NPIC
- IDRCB: 2026-A01727-44 (Outro identificador: Centre Hospitalier Intercommunal Creteil)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .